LRIG2 and non-small cell lung carcinoma: According to the LRIG2 immunoreactive intensity, in the total 116 cases of NSCLC, 80 patients (68.97%) were classified into the low-LRIG2 group, and 36 (31.03%) were classified into the high-LRIG2 group.